Eosinophils as a predictor of mepolizumab treatment responses in COPD

I. Pavord (Oxford, United Kingdom), G. Criner (Philadelphia, PA, United States of America), H. Kerstjens (Groningen, Netherlands), E. Bradford (Research Triangle Park, NC, United States of America), S. Schweiker Harris (Research Triangle Park, NC, United States of America), O. Keene (Stockley Park West, Uxbridge, Middlesex, United Kingdom), B. Mayer (Stockley Park West, Uxbridge, Middlesex, United Kingdom), D. Rubin (Stockley Park West. Uxbridge, Middlesex, United Kingdom), S. Yancey (Research Triangle Park, NC, United States of America), D. Bratton (Stockley Park, Uxbridge, Middlesex, United Kingdom)

Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Pavord (Oxford, United Kingdom), G. Criner (Philadelphia, PA, United States of America), H. Kerstjens (Groningen, Netherlands), E. Bradford (Research Triangle Park, NC, United States of America), S. Schweiker Harris (Research Triangle Park, NC, United States of America), O. Keene (Stockley Park West, Uxbridge, Middlesex, United Kingdom), B. Mayer (Stockley Park West, Uxbridge, Middlesex, United Kingdom), D. Rubin (Stockley Park West. Uxbridge, Middlesex, United Kingdom), S. Yancey (Research Triangle Park, NC, United States of America), D. Bratton (Stockley Park, Uxbridge, Middlesex, United Kingdom). Eosinophils as a predictor of mepolizumab treatment responses in COPD. 1992

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: